Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host

Inclusion Criteria: Induction phase (IM): * Patients aged ≥18 years to 75 years * Patients who underwent allo-SCT for a hematological disorder * Body weight ≥ 40 Kg. * Confirmed diagnosis of cGVHD resistant to at least one systemic immunosuppressive therapy. The diagnosis of cGHVD should be based on the NIH Working Group Consensus (www.asbmt.org/gvhd/index.htm). Grading of cGVHD will be based on clinical manifestations including: 1. ocular, oral and mucosal symptoms; 2. performance status; 3. evaluation of pulmonary functions; 4. cutaneous evaluation; 5. evaluation of musculo-skeletal manifestations; 6. evaluation of liver involvement; * Any source of hematopoietic stem cell is allowed * Both myeloablative and nonmyeloablative conditioning regimens are authorized. * Absence of contra-indications to the use of IM or Nilotinib * Patient having French health care coverage * Female patients of childbearing potential must have before initiation of study drug and agree to have efficient contraceptive precautions throughout the trial and for 3 months after the end of the trial. * Signed informed consent. Salvage phase (Nilotinib) : Patients enrolled in the first phase and who failed to IM: * Patients, who discontinue imatinib mesylate at 3 months for lack of response (no response = stable disease), * those who experience progression at any time, * those who relapse after an initial response at any time * or those who discontinue for toxicity at any time. Exclusion Criteria: * Patient developing acute GVHD (whether early or "late onset" form) * First episode of cGVHD * Patient who received IM or Nilotinib treatment or any other TKI after transplant 3 months before the inclusion on the study * Patient treated by TKI for a GVHD * Contra-indication to IM or Nilotinib * Neutropenia \< 0.5 G/L * Uncontrolled systemic infection which can be associated, according to the investigator, to an enhanced risk of patient's death during the first month of treatment * Severe neurological or psychiatric disorders * Pregnancy or lactation * Known uncontrolled arrhythmias or symptomatic heart disease or left ventricular ejection fraction \< 40% (cardiac tests as clinically indicated) * Recurrence of cancer for which the transplant was done except for presence of minimal residual disease by PCR * Patients with secondary malignancy ≤ 2 years prior study-entry except: * Basal cell carcinoma of the skin * Squamous cell carcinoma of the skin * Carcinoma in situ of the cervix * Carcinoma in situ of the breast * Prostate cancer (Tumor, Node, Metastasis \[TNM\] stage T1a or T1b) * Patients in emergency situation * Patients kept in detention * Patients unable or unwilling to comply with the protocol requirements